Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > Chuikyo Debate on Off-Year Drug Price Revisions
Chuikyo Debate on Off-Year Drug Price Revisions
-
MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
-
Gist of FY2025 Drug Price Revision
December 26, 2024
-
Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
-
Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
-
MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
December 19, 2024
-
MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
December 19, 2024
-
Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
Discussions on Generic Company Indices Make Headway towards Full Rollout in Next Revision
December 13, 2024
-
Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
-
Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
-
Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
December 5, 2024
-
(Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
-
Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
-
Off-Year Debate “Won’t Progress” without Industry’s Behavioral Change: JMA Rep
September 26, 2024
-
Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
August 8, 2024
-
Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
August 8, 2024
-
Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
-
Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s drug pricing panel on November 19 discussed a wide range of potential pricing changes related to patent-protected medicines, including…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…